Terapia celulară CAR-T

In the world of cancer treatment, there’s a groundbreaking approach called CAR-T cell therapy. It’s a new way to fight cancer that’s giving hope to many people. But what exactly is CAR-T therapy? How does it work, and why is it such a big deal?

Here we’re going to explore CAR-T cell therapy in simple terms. We’ll learn how it’s changing the game in cancer treatment and why it’s so important. So, let’s dive in and discover the promise of CAR-T cell therapy.

Understanding CAR-T Cell Therapy

CAR-T cell therapy is a groundbreaking form of immunotherapy that harnesses the power of the immune system to target and destroy cancer cells. CAR-T stands for chimeric antigen receptor T-cell therapy. Here’s an overview of how it works and its mechanism of action:

CAR-T Cells: CAR-T cells are engineered immune cells derived from a patient’s own T cells. T cells are a type of white blood cell that play a key role in the immune response. In CAR-T therapy, these T cells are modified to express chimeric antigen receptors (CARs) on their surface.

How does CAR-T Therapy Works?

• Collection: T cells are collected from the patient’s blood through a process called leukapheresis.
• Engineering: The collected T cells are then modified in the laboratory to express CARs. This is typically done using viral vectors to introduce the gene encoding the CAR into the T cells.
• Expansion: The engineered CAR-T cells are grown and expanded in the laboratory to produce a large number of cells.
• Infusion: The expanded CAR-T cells are infused back into the patient’s bloodstream. Once inside the body, these cells can recognize and target cancer cells.

Mechanism of Action

• Targeting Cancer Cells: The CARs on the surface of CAR-T cells are designed to recognize specific proteins, called antigens, that are found on the surface of cancer cells. When the CAR-T cells encounter cancer cells that express these antigens, they become activated and initiate an immune response against the cancer.
• Activation and Killing: Once activated, CAR-T cells release cytokines and cytotoxic molecules that directly kill the cancer cells. Additionally, CAR-T cells can also recruit other immune cells to the site of the tumor to enhance the anti-cancer immune response.
• Persistence: Some CAR-T cells can persist in the body for months or even years after infusion, providing long-term surveillance against cancer recurrence.

What Cancers can be treated with CAR-T Cell Therapy?

CAR-T cell therapy has shown promising results in the treatment of certain types of cancer, particularly hematologic malignancies. Some of the cancers that can be treated with CAR-T cell therapy include:

• Acute Lymphoblastic Leukemia (ALL): CAR-T cell therapy has been particularly successful in treating relapsed or refractory ALL, especially in children and young adults. CAR-T cells targeting the CD19 antigen have shown remarkable efficacy in inducing remission in patients who have not responded to conventional treatments.
• Non-Hodgkin Lymphoma (NHL): Certain types of NHL, such as diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma, have been responsive to CAR-T cell therapy. CAR-T cells targeting the CD19 antigen have demonstrated significant clinical benefit in patients with relapsed or refractory NHL.
• Multiple Myeloma: CAR-T cell therapy targeting the B-cell maturation antigen (BCMA) has shown promising results in patients with relapsed or refractory multiple myeloma. BCMA-targeted CAR-T cells have demonstrated deep and durable responses in clinical trials, leading to their expedited development for multiple myeloma treatment.
• Chronic Lymphocytic Leukemia (CLL): While CLL has proven to be more challenging to treat with CAR-T cell therapy compared to ALL and NHL, ongoing research is exploring ways to enhance the efficacy of CAR-T cells in CLL. CD19-targeted CAR-T cells are being investigated in clinical trials, and advancements in CAR-T cell design and combination therapies hold promise for improving outcomes in CLL patients.
• Other Hematologic Malignancies: CAR-T cell therapy is also being investigated for the treatment of other hematologic malignancies, including mantle cell lymphoma, hairy cell leukemia, and T-cell lymphomas. Clinical trials are evaluating the safety and efficacy of CAR-T cell therapy in these diseases.
• Solid Tumors: While the success of CAR-T cell therapy in solid tumors has been more limited compared to hematologic malignancies, research in this area is ongoing. CAR-T cell therapy targeting solid tumors faces challenges such as identifying suitable target antigens and overcoming the immunosuppressive tumor microenvironment.

CAR-T Cell Therapy Success Story

CAR-T cell therapy has provided remarkable success stories, transforming the lives of patients who had exhausted conventional treatment options. Here is one notable example: